Bioxyne Limited · ASX:BXN
Bioxyne — Investor Presentation (September 2024)
21 slides from Bioxyne's investor presentation, Sep 18, 2024
Slide 1: Becoming Australia's leading manufacturer & wholesaler of novel medicines
For personal use only Be c o m in g Au s t ra lia ’s le a d in g m a n u fa c t u re r & wh o le s a le r o f n o ve l m e d ic in e s ASX:BXN Inve s t or Pre s e nt at ion | Se p t e m b e r 20 24 Bioxyne | ASX:BXN | Inve s t or Pre s e nt at ion | Se p t e m b e r 20 24 | 1
Slide 2: Important Notice and Disclaimer
Im p o rt a n t No t ic e a n d Dis c la im e r This p re s e ntation (Pre s e ntation) has b e e n p re p are d b y Bioxyne Limite d ABN 9 7 0 84 46 4 19 3 (Bioxyne or the Comp any). The information in this Pre s e ntation is of a ge ne ral b ac kground nature , is in s ummary form and d oe s not p
Slide 3: Investment Highlights
In ve s t m e n t High ligh t s For personal use only St ro n g re ve n u e gro wt h Ho ld s e xt e n s ive GMP Firs t c o m p a n y lic e n s e d Dive rs ifie d c o re o f re c ord ing an 8 1% lift t o lic e n s e is s ue d b y TGA for b y TGA in Aus t ralia t o h e a lt h c a re & we lln e s s $9
Slide 4: Executive Summary
Exe c u t ive Su m m a ry Bio xyn e is p o s it io n e d t o b e c o m e Au s t ra lia ’s le a d in g m a n u fa c t u re r & wh o le s a le r o f n o ve l m e d ic in e s in c a n n a b is & p s yc h e d e lic s For personal use only ~36 % $9 .6 6 m FY24 Gros s Profit Margin Tot al Re ve nue for FY
Slide 5: Significant Global Distribution & Sales Capabilities
Sign ific a n t Glo b a l Dis t rib u t io n & Sa le s Ca p a b ilit ie s Bio xyn e h a s For personal use only e s t a b lis h e d a glo b a l s u p p ly , m a n u fa c t ure a n d d is t rib u t io n n e t wo rk, n o w ra p id ly s c a lin g re ve n u e s t o s e rvic e b o t h t h e B2B & B2C m a
Slide 6: Growth Strategy
For personal use only Gro wt h St ra t e gy Bioxyne | ASX:BXN | Inve s t or Pre s e nt at ion | Se p t e m b e r 20 24 | 6
Slide 7: Commercial Milestones to Date
Co m m e rc ia l Mile s t o n e s t o Da t e For personal use only Ac q uis it ion of La unc h Ca nXCha nge Com p le t e d PICs GMP St ra t e gic a llia nc e wit h CY BLS m a nufa c t ure s Prod uc t ion & s up p ly Bre a t he Life p rovid ing a c c re d it e d fa c ilit y in QLD, wit h Biop ha rm a
Slide 8: B2C Business Model
B2C Bu s in e s s Mo d e l SOURCING Ce rt ifie d c ult iva t ors & s up p lie rs a round t he For personal use only world t o d e live r only t he b e s t APIs & s t a rt ing m a t e rials MANUFACTURING ISO- a c c re d it e d c le a n room s & GMP s t a nd a rd s t o m e e t int e rna t iona l q ua
Slide 9: B2B Business Model
B2B Bu s in e s s Mo d e l SOURCING Ce rt ifie d c ult iva t ors & s up p lie rs a round t he world For personal use only t o d e live r only t he b e s t APIs & s t a rt ing m a t e rials CERTIFIED MANUFACTURING ISO- a c c re d it e d c le a n room s & GMP c e rt ific a t ion t o m e e t int e rna
Slide 10: Growth Plan to Profitability in FY25 Focused on Diversified Revenue Base
Gro wt h Pla n t o Pro fit a b ilit y in FY25 Fo c u s e d o n Dive rs ifie d Re ve n u e Ba s e B2B Non- Gro wt h & p ro fit a b ilit y d rive n b y 3 ke y s e gm e n t s For personal use only p harm ac e ut ic als 17% Fo re c a s t B2B re ve n u e b y Pharm ac e ut ic als Se gm e n t 6 1% (20 25 )
Slide 11: Near-Term Growth Strategy
Ne a r- Te rm Gro wt h St ra t e gy CY24 CY25 For personal use only • Be c om e m arke t le ad e r in AUS for GMP m anufac t ure of “Sp e c ials ” • Manufac t ure 10 ,0 0 0 kg of THC flowe r p rod uc t s • Se c ure UK lic e ns e s for Sp e c ials (Cannab is ) for Aus t ralian p at ie nt s Me d ic in
Slide 12: Financial Overview
For personal use only Fin a n c ia l Ove rvie w Bioxyne | ASX:BXN | Inve s t or Pre s e nt at ion | Se p t e m b e r 20 24 | 12
Slide 13: FY24 Financial Performance
FY24 Fin a n c ia l Pe rfo rm a n c e ¹ St ro n g p e rfo rm a n c e fro m p ro vis io n o f p s y c h o a c t ive m e d ic in e s , s u p p le m e n t s a n d fo o d s m a d e fro m For personal use only c a n n a b is , p s ilo c yb in & MDMA BXN REVENUS FROM OEPRATIONS ($ 0 0 0 ’s ) $25,0 0 0 10
Slide 14: Cost Savings Initiatives
Co s t Sa vin gs In it ia t ive s Se ve ra l c o s t - s a vin g in it ia t ive s h a ve b e e n im p le m e n t e d t h ro u gh o u t FY24 , wh ic h will c o n t in u e t o d rive For personal use only fin a n c ia l im p ro ve m e n t in t o FY25 $0 .30 m $0 .5 9 m In c os t s avings following In
Slide 15: Approaching Profitability
Ap p ro a c h in g Pro fit a b ilit y St ro n g o u t lo o k fo r FY25 a n d b e y o n d , fo llo win g s ign ific a n t c o s t re s t ru c t u re wit h a n t ic ip a t e d s t ro n g For personal use only gro wt h a c ro s s c o re b u s in e s s ve rt ic a ls t o d e live r p o s it ive c a s h f
Slide 16: Market Opportunity
For personal use only Ma rke t Op p o rt u n it y Bioxyne | ASX:BXN | Inve s t or Pre s e nt at ion | Se p t e m b e r 20 24 | 16
Slide 17: Focused Development of New Treatment Options for Patients
Fo c u s e d De ve lo p m e n t o f Ne w Tre a t m e n t Op t io n s fo r Pa t ie n t s Un re s p o n s ive t o Co n ve n t io n a l Th e ra p ie s Su b s t a n t ia l o p p o rt u n it y fo r p o t e n t ia l d e p re s s io n t h e ra p ie s fro m p s ilo c y b in a n d MDMA For personal use only
Slide 18: Appendix
For personal use only Ap p e n d ix Bioxyne | ASX:BXN | Inve s t or Pre s e nt at ion | Se p t e m b e r 20 24 | 18
Slide 19: Experienced Leadership Team
Exp e rie n c e d Le a d e rs h ip Te a m For personal use only Mr. An t h o n y Ho Sa m u e l Wa t s o n J a s o n Hin e Gu y Ro b e rt s o n B. Com (UNSW), CA, FAICD, FCIS, FGIA BSc Financ e and Ec onomic s BA Ec onomic s and Comme rc e B. Com (Hons .) CA Non- e xe c ut ive Chairm an Managing Dire
Slide 20: Corporate Overview
Co rp o ra t e Ove rvie w $0 .0 30 18 0 m For personal use only $0 .0 20 120 m $0 .0 10 60 m - - Se p - 23 De c - 23 Ma r- 24 J un- 24 Se p - 24 Volum e Share Pric e CORPORATE SNAPSHOT (17/ 0 9 / 20 24 ) MAJ OR SHAREHOLDERS Sh a re h o ld e r Sh a re s (m ) % Sh a re s o n Is s u e ~2,0 4 7m Bre at
Slide 21: Contact
For personal use only Co n t a c t : Sam ue l Wat s on – Managing Dire c t or info@b ioxyne .c om J am e s Em ons on – Corp orat e Ad vis or, Alp ine Cap it al je m ons on@alp ine c ap it al.au Bioxyne | ASX:BXN | Inve s t or Pre s e nt at ion | Se p t e m b e r 20 24 | 21